We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Rep. Rosa DeLauro (D-Conn.), the incoming chairwoman of the subcommittee with jurisdiction over the FDA's budget, has a number of changes in mind for the agency, starting with an improved drug review system, the lawmaker says.
Bristol-Myers Squibb (BMS) and AstraZeneca announced that they are collaborating to develop and commercialize two experimental drugs for Type 2 diabetes.
The House has passed a bill that would extend federal funding for research on stem cells beyond the preexisting cell lines that the Bush administration approved funding for in August 2001.
In the last year, more out-of-court settlements between generic and brand companies involved reverse payment deals than in the two previous years combined, according to a new FTC report.
A bipartisan group of House and Senate lawmakers have reintroduced legislation from the last congressional session that would allow limited importation of prescription drugs.
Sen. Chuck Grassley (R-Iowa), one of the most vocal opponents of government negotiation of Medicare costs, is considering using a filibuster to stop bipartisan direct negotiation legislation because he believes that its proponents may now have the votes to pass it.
A panel of drug industry representatives presented their views on the effects of reverse-payment deals before federal lawmakers at a Senate hearing called to consider proposed legislation that could stop the practice of paying generic drug companies to limit market competition.
Healthcare spending in the U.S. totaled almost $2 trillion in 2005, or $6,697 per person, with total spending for prescription drugs in 2005 pegged at $200.7 billion, the Centers for Medicare & Medicaid Services (CMS) reported.
The public continues to lose trust in the pharma industry, viewing it far differently than the industry perceives itself, according to a new PricewaterhouseCoopers report.